Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.

Shoko Kitazawa Tatsuyuki Chiyoda Kohei Nakamura Kensuke Sakai Tomoko Yoshihama Hiroshi Nishio Yusuke Kobayashi Takashi Iwata Kouji Banno Wataru Yamagami Hiroshi Nishihara Daisuke Aoki

Published in: International journal of clinical oncology (2023)

Through multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients' prognosis and performance status should be considered before performing the test.

Keyphrases

endometrial cancer
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
gene expression
patient reported outcomes
papillary thyroid
lymph node metastasis
genome wide identification